Dr Jacobs on the Preliminary Efficacy of TNB-486 in R/R Follicular Lymphoma
Ryan Jacobs, MD, hematologist and medical oncologist, Levine Cancer Institute, Atrium Health, discusses early responses with the novel CD19 and CD3 T-cell engager TNB-486 in relapsed/refractory follicular lymphoma according to a phase 1 study.